Drug Profile

ALG 000184

Alternative Names: ALG-000184

Latest Information Update: 23 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aligos Therapeutics
Class Antivirals; Hepatoprotectants; Small molecules
Mechanism of Action Capsid protein modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Hepatitis B

Most Recent Events

09 May 2025 Aligos Therapeutics plans the phase II B-SUPREME trial for Hepatitis B (Treatment-naive) (PO, Tablet) in May 2025 (NCT06963710)
08 May 2025 Updated efficacy data from a phase I trial in Hepatitis B released by Aligos Therapeutics
06 May 2025 Aligos Therapeutics completes phase-I clinical trials in Hepatitis B (Combination therapy) in Mauritius, Australia, UK, China, New Zealand, Moldova, Hong Kong (PO), before May 2025 (NCT04536337)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com